We evaluated three clinical factors, namely, CHAARTED risk classifications (high‐volume disease [HVD] vs low‐volume disease [LVD]), Gleason scores (GS, 9‐10 vs ≤8), and hemoglobin (Hb, ≤13.0 g/dL vs >13.0 g/dL), for their prognostic potential in predicting time to castration‐resistant prostate cancer (TTC) and overall survival (OS) of mHNPC patients by multivariate analysis. Here, GSTM1 is linked to glycogen storage disease VI.